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A major barrier to successful antitumor vaccination is tolerance of high-avidity T cells 
specific to tumor antigens. In keeping with this notion, HER-2/neu (neu)-targeted vaccines, 
which raise strong CD8
 
 
 
 T cell responses to a dominant peptide (RNEU
 
420-429
 
) in WT FVB/N 
mice and protect them from a neu-expressing tumor challenge, fail to do so in MMTV-
 
neu
 
 
(
 
neu
 
-N) transgenic mice. However, treatment of 
 
neu
 
-N mice with vaccine and 
cyclophosphamide-containing chemotherapy resulted in tumor protection in a proportion of 
mice. This effect was specifically abrogated by the transfer of 
 
neu
 
-N–derived CD4
 
 
 
CD25
 
  
 
T cells. RNEU
 
420-429
 
-specific CD8
 
 
 
 T cells were identified only in 
 
neu
 
-N mice given vaccine 
and cyclophosphamide chemotherapy which rejected tumor challenge. Tetramer-binding 
studies demonstrated that cyclophosphamide pretreatment allowed the activation of high-
avidity RNEU
 
420-429
 
-specific CD8
 
 
 
 T cells comparable to those generated from vaccinated 
FVB/N mice. Cyclophosphamide seemed to inhibit regulatory T (T reg) cells by selectively 
depleting the cycling population of CD4
 
 
 
CD25
 
 
 
 T cells in 
 
neu
 
-N mice. These findings 
demonstrate that 
 
neu
 
-N mice possess latent pools of high-avidity neu-specific CD8
 
 
 
 T cells 
that can be recruited to produce an effective antitumor response if T reg cells are blocked or 
removed by using approaches such as administration of cyclophosphamide before vaccination.
 
Central and peripheral mechanisms of T cell tol-
erance must exist to prevent autoimmunity
(1–3). However, these same mechanisms are
likely contributors to ineffective T cell responses
often observed in cancer patients (4). CD8
 
 
 
 T
cells specific for tumor antigens have been de-
tected in patients. In particular, HER-2/neu
(neu)-specific T cells have been isolated from
patients with breast and ovarian cancer (5). In ad-
dition, p53-specific T cells have been isolated
from patients with colorectal carcinomas, human
papilloma virus–specific T cells have been iso-
lated from patients with cervical cancer, and T
cells specific for more than 10 different antigens
have been isolated from patients with melanoma
(6). Although these T cell responses are often
observed in patients who have been treated with
an antigen-specific vaccine, most are weak and
ineffective in controlling tumor growth. In some
instances, this ineffectiveness may result from an
ineffective vaccine approach. However, because
the majority of tumor-associated antigens are
either overexpressed or reactivated developmen-
tal self-antigens, tolerance to specific tumor
antigens is a likely mechanism for blunted T cell
responsiveness in many cases (7, 8).
Intrathymic expression of self-antigens often
leads to central deletion of T cells that express
high-avidity TCR specific for these antigens.
However, T cells that express lower-avidity
TCR for these antigens can escape into the
periphery (9). In addition, both high-avidity
and low-avidity T cells specific for peripherally
expressed self-antigens will leave the thymus
rather than undergo deletion (10). Therefore,
peripheral (extrathymic), nondeletional mech-
anisms exist that render T cells specific for self-
tissues ignorant or functionally impaired (11–13).
Understanding the mechanisms of peripheral tol-
erance in the context of tumor antigens is crit-
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ical for the development of interventions that can reverse the
tolerant state and allow these T cells to respond more effec-
tively to tumors. In particular, it is critical to determine
whether there are latent pools of tumor-specific T cells in
tumor-tolerant individuals that are capable of being coaxed
into a functionally active state.
Several murine models are available for dissecting mecha-
nisms of peripheral tolerance (14). Extending this approach to
a relevant tumor antigen, we recently described the existence
of immune tolerance in the HER-2/
 
neu
 
 transgenic (
 
neu
 
-N)
mouse model of breast cancer. These mice overexpress the
rat protooncogene 
 
neu
 
 and develop spontaneous mammary
tumors between 4 and 8 mo of age (15). Similar to observa-
tions in patients with breast and ovarian cancers (5), 
 
neu
 
-N
mice exhibit down-regulated immune responses after neu-
targeted vaccination. Specifically, 
 
neu
 
-N mice develop poor
antibody and T cell responses to neu regardless of the neu-
targeted vaccination approach used when compared with pa-
rental FVB/N mice receiving the same vaccine (16). The
presence of the transgene does not result in complete central
deletion of neu-specific T cells in 
 
neu
 
-N mice, because anti-
neu activity is detected. However, the possibility remains that
subpopulations of high-avidity neu-specific T cells are de-
leted centrally, whereas T cells with lower avidity can leave
the thymus but are subject to peripheral mechanisms of toler-
ance. Alternatively, tolerization of all neu-specific T cells may
take place completely in the periphery. Various models of an-
tigen-specific tolerance support all of these hypotheses.
We previously reported that treatment of 
 
neu
 
-N mice with
immune modulating doses of cyclophosphamide-containing
chemotherapy before vaccination resulted in tumor protection
in 10–30% of mice (17). Here we show that the vaccine-
enhancing effect of cyclophosphamide is mediated through se-
lectively inhibiting the cycling population of CD4
 
 
 
CD25
 
 
 
regulatory T (T reg) cells in 
 
neu
 
-N mice. Furthermore, high-
avidity RNEU
 
420-429
 
-specific CD8
 
 
 
 T cells are not deleted in
the periphery, as previously thought. Instead, these high-avid-
ity T cells can be recruited and activated to provide a potent
antitumor immune response if T reg cells are inhibited.
 
RESULTS
Adoptive transfer of CD4
 
 
 
CD25
 
 
 
 regulatory T cells inhibits 
the antitumor immune response induced by 
cyclophosphamide given with vaccine
 
We previously demonstrated that 10–30% of tolerized 
 
neu
 
-N
mice can be cured of neu-expressing tumors when treated
Figure 1. Adoptive transfer of CD4 CD25  T reg cells abrogates 
the immune modulatory effect of cyclophosphamide. 10 neu-N mice/
group were vaccinated with either 3T3neuGM alone on day 0 or with 
cyclophosphamide on day  1 and 3T3neuGM on day 0. Adoptively trans-
ferred T cells were given on day 13, as described in Materials and methods. 
On day 14, all mice were challenged with NT2 tumor cells. Mice were mon-
itored for tumor outgrowth two times/wk. (A) cyclophosphamide given 
before vaccine results in significant protection (P   0.001) from NT tumor 
challenge. Adoptively transferred, purified CD8  splenocytes (B) were not 
capable of suppressing the effect of cyclophosphamide, whereas CD4  
splenocytes (C) did significantly inhibit the immune modulatory effects of 
cyclophosphamide in a dose-dependent fashion (P   0.005 for 107 CD4 ). 
(D) The experiment was repeated using purified CD4 CD25  splenocytes 
and purified CD4 CD25  splenocytes. A significant suppressive effect of 
the T cells localized to the CD4 CD25  splenocytes (P   0.001), and not 
to the CD4 CD25  splenocytes (P   0.611). Each study was repeated at 
least twice with similar results. Cy, cyclophosphamide. 
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with immune-modulating doses of cyclophosphamide che-
motherapy in sequence with neu-targeted vaccination. In
contrast, all 
 
neu
 
-N mice given vaccine alone develop tumors
(17). T reg cells probably play a role in suppressing antigen-
specific T cell responses (3). It has been suggested for more
than 20 yr, and addressed more recently, that immune-
modulating doses of cyclophosphamide may function by in-
hibiting suppressor T cell activity (18–21). We therefore
evaluated T reg cells as a mechanism by which vaccine-
induced immunity is suppressed in 
 
neu
 
-N mice. 
 
Neu
 
-N
mice were given vaccine, alone or with cyclophosphamide,
and then tumor challenged 2 wk later. Pretreatment with
cyclophosphamide significantly enhanced the vaccine effect
(P 
 
 
 
 0.001) compared with mice given vaccine alone (Fig.
1 A). To determine if cyclophosphamide pretreatment elim-
inates a suppressive T cell population, 
 
neu
 
-N mice that were
given cyclophosphamide and vaccine received adoptively
transferred CD8
 
 
 
 T cells (either 10
 
6
 
 or 5 
 
 
 
 10
 
6
 
 total per
mouse; Fig. 1 B), or CD4
 
 
 
 T cells (either 10
 
6
 
 or 10
 
7
 
 total
per mouse; Fig. 1 C) 1 d before tumor challenge. Initial ex-
periments used T cells isolated from the spleens of tumor-
bearing donor 
 
neu
 
-N mice vaccinated 14 d before adoptive
transfer. Because no enrichment of the transferred cells
based on antigen specificity could be performed, we rea-
soned that any suppressive population would be activated in
the vaccinated tumor-bearing donors. Neither dose of
CD8
 
 
 
 T cells abrogated the antitumor response in the cy-
clophosphamide- and vaccine-treated mice (Fig. 1 B).
However, CD4
 
 
 
 T cells from donor 
 
neu
 
-N mice signifi-
cantly suppressed the antitumor responses induced by cyclo-
phosphamide and vaccine (P 
 
 
 
 0.005) when 10
 
7
 
 cells were
transferred (Fig.
 
 
 
1 C). In subsequent experiments, T cells
isolated from naive 
 
neu
 
-N mice were used for the adoptive
transfer, yielding the same results (unpublished data). These
data suggest that there is a subset of CD4
 
 
 
 T cells with T
reg cell function that inhibit the activity of tumor-rejecting,
neu-specific T cells. In a second set of studies, mice received
CD4
 
 
 
CD25
 
 
 
 T cells (10
 
7
 
 total per mouse) or CD4
 
 
 
CD25
 
 
 
T cells (10
 
6
 
 total per mouse). The CD4
 
 
 
CD25
 
 
 
 T cell pop-
ulation failed to inhibit cyclophosphamide-modulated anti-
tumor immunity (P 
 
 
 
 0.611), whereas the CD4
 
 
 
CD25
 
 
 
 T
cell population completely abrogated the antitumor im-
mune response even at a 10-fold-lower dose (P 
 
 
 
 0.001;
Fig. 1 D). The suppressive activity of the CD4
 
 
 
CD25
 
 
 
 T
cell subset was confirmed by in vitro proliferation assay in
coculture with CD4
 
 
 
CD25
 
 
 
 T cells (22) and detection of
 
foxp3
 
 expression by RT-PCR (reference 23 and unpub-
lished data).
 
Vaccine combined with cyclophosphamide chemotherapy 
uncovers T cells specific for the immunodominant epitope 
RNEU
 
420-429
 
, directly correlating RNEU
 
420-429 T cell activity 
with in vivo tumor rejection
In nontolerized FVB/N mice, neu-targeted vaccine will
completely cure mice from a neu-expressing tumor chal-
lenge. In vivo rejection of tumor is associated with a neu-
specific CD8  T cell repertoire that is directed at the immu-
nodominant T cell epitope RNEU420-429  (24). We have
shown that the RNEU420-429-specific CD8  T cells are capa-
ble of lysing neu-expressing tumors in vitro and eradicating
neu-expressing tumors in FVB/N mice in vivo. However,
activated RNEU420-429-specific T cells are rarely detected
in vaccinated neu-N mice (24). Because cyclophosphamide
chemotherapy combined with vaccine cures 10–30% of neu-N
mice, we hypothesized that the curative effect was caused by
the cyclophosphamide chemotherapy regimen activating
RNEU420-429-specific T cells. Tumor-challenged neu-N
mice were given vaccine with or without cyclophosphamide
chemotherapy and followed for development of neu-express-
Figure 2. RNEU420-429-specific T cells can be identified in poly-
clonal T cell populations from neu-N mice given vaccine and cyclo-
phosphamide chemotherapy that rejected neu-expressing tumors. 
(A) Eight neu-N mice/group were tumor challenged on day  3, followed 
on day 0 by vaccination with or without cyclophosphamide chemotherapy. 
Mice were monitored for tumor outgrowth two times/wk. All mice that 
received mock vaccine with or without cyclophosphamide chemotherapy 
developed tumor by day 35 (not depicted). (B) At the end of the experi-
ment in (A), splenic T cells were isolated, and reactivity to RNEU420-429 was 
determined by ICS. Plotted is the percentage of CD8  T cells that secreted 
IFN-  in response to RNEU420-429 minus the percentage responding to 
NP118-126. This experiment was repeated at least three times with similar 
results. Cy, cyclophosphamide.UNCOVERING HIGH-AVIDITY CD8  T CELLS IN A TOLERANT HOST | Ercolini et al. 1594
ing mammary tumors. As previously reported, cyclophos-
phamide chemotherapy resulted in a significant enhance-
ment of the vaccine effect (P   0.002), and 25% of mice
receiving vaccine and cyclophosphamide chemotherapy re-
mained tumor-free (Fig. 2 A; reference 17). These mice
were killed on day 50, and intracellular cytokine staining
(ICS) was performed to assess recognition of RNEU420-429 in
both tumor-bearing and tumor-free mice. As shown in Fig.
2 B, the two tumor-free neu-N mice (mouse E and mouse F)
showed the highest percentage of RNEU420-429-specific
CD8  T cells. The tumor-bearing mice (mice A–D) showed
no activation above the background observed in the neu-N
mice given vaccine alone. Thus, cyclophosphamide chemo-
therapy combined with vaccine seems to activate RNEU420-429-
specific T cells in the neu-N mice, enabling them to reject
the neu-expressing tumor challenge. Similar activation of
RNEU420-429-specific T cells was observed in tumor-free
neu-N mice given cyclophosphamide alone with vaccine
(unpublished data).
Because the presence of RNEU420-429-specific T cells
could result simply from a boosting effect of having success-
fully rejected the neu-expressing tumor, we determined if
RNEU420-429-specific T cells could be detected in neu-N
mice given cyclophosphamide chemotherapy in the absence
of a tumor challenge. RNEU420-429-specific CD8  T cell re-
sponses were detected in 20–30% of these mice (unpublished
data), correlating well with our previous data measuring the
antitumor effect of vaccine and cyclophosphamide chemo-
therapy in tumor-bearing neu-N mice (17). Thus, T cells
specific for the immunodominant epitope, RNEU420-429, can
be detected after treatment with cyclophosphamide chemo-
therapy and vaccine in tumor naive neu-N mice.
Figure 3. FVB/N and neu-N–derived CD8  T cell lines are specific 
for RNEU420-429 but differentially lyse neu-expressing mammary tumors 
despite expressing similar levels of cell surface markers. (A) T cell lines 
were derived from vaccinated FVB/N mice (FVB/N line), neu-N were mice 
given vaccine alone (neu-N line), or neu-N mice were given vaccine and 
cyclophosphamide chemotherapy that had rejected an NT tumor challenge 
(neu-N plus chemotherapy line). IFN-  ICS was performed after T cells were 
stimulated overnight with equal numbers of T2Dq cells pulsed with 
either the irrelevant peptide NP118-126 (shaded histogram) or with RNEU420-429 
(black line). (B) CTL assay using the three T cell lines and neu-expressing NT2 
tumor targets. These experiments were repeated more than six times with 
similar results. (C) Cells were stained with antibodies to CD3, CD8 , TCR 
V 2, TCR V 4, and TCR V 6 as described in Materials and methods. Black line, 
FVB/N line; dashed line, neu-N line; gray line, neu-N plus chemotherapy line.JEM VOL. 201, May 16, 2005 1595
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Comparison of RNEU420-429-specific CD8  T cell lines from 
vaccinated FVB/N and neu-N mice reveal differences in 
T cell avidity that may explain the enhanced therapeutic 
effect of cyclophosphamide chemotherapy and vaccine in 
the neu-N mice
CD8  T cell lines were generated after neu-targeted vaccina-
tion in FVB/N and neu-N mice. All lines were generated by
repeated in vitro stimulation with 3T3neuB7-1 target cells
that contain the entire neu cDNA. Initial analysis of T cell
lines derived from the vaccinated FVB/N and neu-N mice, as
well as neu-N mice given vaccine and cyclophosphamide
chemotherapy, revealed that all are specific for the RNEU420-429
peptide (Fig. 3 A). In contrast, these lines did not recognize
the irrelevant H-2Dq-binding peptide NP118-126  (25). To
characterize functional differences between the FVB/N-
derived and the neu-N–derived T cell lines, a more rigorous
analysis directly comparing the three T cell lines was per-
formed. Each T cell line was evaluated for the ability to lyse
NT2 mammary tumor cells, which express naturally pro-
cessed neu peptides. The RNEU420-429-specific T cell line de-
rived from vaccinated neu-N mice was less effective at lysing
tumor cells than the lines derived from vaccinated FVB/N
mice and from neu-N mice given vaccine and cyclophospha-
mide chemotherapy (Fig. 3 B). The T cell lines were all
 99% CD8  and expressed comparable surface levels of
TCR, CD8 , and CD3 (Fig. 3 C). Because these lines are
comparable in the degree of peptide specificity and TCR,
CD8 , and CD3 levels, we hypothesized that the difference
in tumor lysis could be caused by a difference in avidity of
TCR for the H-2Dq/RNEU420-429 MHC/peptide complex.
To address this issue, we stained the three T cell lines
with decreasing concentrations of the H-2Dq-RNEU420-429
tetramer. This study revealed that the T cells derived from
neu-N mice given vaccine alone stained with a much lower
intensity than the FVB/N-derived T cells. T cells derived
from neu-N mice given vaccine and cyclophosphamide che-
motherapy showed a staining profile similar to the FVB/
N-derived line (Fig. 4 A). Even a 10-fold dilution of the tet-
ramer resulted in loss of staining of the neu-N T cell line,
whereas the other two lines showed staining even at a 100-
fold dilution of the tetramer. Further quantitation revealed
that at least 16  M of tetramer complex was required to
stain the T cell line derived from vaccinated neu-N mice. In
contrast, only 0.16  M of tetramer was required to demon-
strate similar staining of the FVB/N-derived T cell line and
of the T cell line derived from neu-N mice given vaccine
and cyclophosphamide chemotherapy. Additionally, binding
kinetics studies were performed by binding tetramer to T
cell lines and competing it off with the H-2Dq-specific anti-
body 30–5-7S (26). As shown in Table I, the dissociation
rate constant (koff) for the neu-N line was roughly sixfold
higher than that of the FVB/N line and the T cell line de-
rived from neu-N mice given vaccine and cyclophosphamide
chemotherapy. Other reports have indicated that the expres-
sion level of CD8  influences functional avidity (27). How-
ever, in our studies, no difference in CD8  staining was ob-
served between the T cell lines from the neu-N mice given
vaccine alone and the neu-N mice given vaccine and cyclo-
phosphamide chemotherapy (Fig. 4 B). These data strongly
support our hypothesis that the neu-N–derived T cell line
has a lower avidity for the MHC class I/RNEU420-429
epitope complex than the FVB/N-derived T cell line or the
T cell line derived from vaccine and cyclophosphamide che-
motherapy treated neu-N mice. Importantly, low avidity
correlated with reduced lysis of the neu-expressing mam-
mary tumor (Fig. 3 B).
High-avidity RNEU420-429-specific T cells are detected in a 
polyclonal population of splenic T cells isolated from neu-N 
mice given vaccine and cyclophosphamide chemotherapy
The data analyzing T cell lines suggest that treatment with im-
mune-modulatory doses of cyclophosphamide chemotherapy
before vaccination results in the recruitment of functional
high-avidity neu-specific T cells in up to 30% of neu-N mice.
The studies analyzing splenic T cells from neu-N mice dem-
onstrate that RNEU420-429-specific T cells can be isolated from
a polyclonal T cell response after vaccine combined with cy-
clophosphamide chemotherapy (Fig. 2 B). To demonstrate
that these RNEU420-429-specific T cells are high avidity, 42
Figure 4. RNEU420-429–specific CD8  T cell lines derived from FVB/N 
and neu-N mice demonstrate quantitatively different avidities for 
the H-2Dq/RNEU420-429 MHC/peptide complex but no difference in 
CD8  staining. (A) The three T cell lines were stained with decreasing 
amounts of H-2Dq/ RNEU420-429 tetramer. Shown is the tetramer staining 
of gated CD8  T cells. Black solid line, 1:5 tetramer dilution; dashed line,
1:50 tetramer dilution; gray line, 1:500 tetramer dilution; shaded, no tetramer. 
(B) T cell lines from neu-N mice given vaccine alone (dashed line) and 
neu-N mice given cyclophosphamide chemotherapy (gray line) were 
stained for CD8  on day 6 after stimulation.UNCOVERING HIGH-AVIDITY CD8  T CELLS IN A TOLERANT HOST | Ercolini et al. 1596
additional tumor-challenged neu-N mice were vaccinated in
sequence with cyclophosphamide chemotherapy and moni-
tored for tumor development. As expected, 20% of the mice
remained tumor-free (unpublished data). On day 56, spleno-
cytes were isolated from tumor-bearing and tumor-free mice,
and reactivity to RNEU420-429 was assessed by ICS after one in
vitro stimulation (unpublished data). TCR avidity was deter-
mined by dilutional tetramer staining of splenocytes from vac-
cinated FVB/N mice, tumor-free neu-N mice given vaccine
and cyclophosphamide chemotherapy, and tumor-bearing
neu-N mice given vaccine alone (included as a negative
control to show background tetramer staining because no re-
activity to RNEU420-429 was observed by ICS). RNEU420-429-
specific T cells from the vaccinated FVB/N mice and cyclo-
phosphamide chemotherapy–treated neu-N mice exhibited
equivalent tetramer staining, comparable to the tetramer stain-
ing observed in the high-avidity T cell lines (Fig. 5). These
staining studies were performed by first gating on CD8  T
cells that are CD62Llo, demonstrating that the tetramer-posi-
tive RNEU420-429-specific T cells are activated. We therefore
conclude that the CD8  T cell responses to neu in parental
FVB/N mice, but not in tolerized neu-N mice, are dominated
by high-avidity T cells specific for RNEU420-429. In addition,
immune-modulating doses of cyclophosphamide chemother-
apy given in sequence with neu-targeted vaccination can un-
cover activated, high-avidity T cells specific for the immuno-
dominant neu epitope in neu-N tolerized mice.
Cyclophosphamide exerts its effect predominantly on cycling 
CD4 CD25  T cells
To understand the mechanism of action of cyclophospha-
mide on CD4 CD25  T cells better, the total number of
CD4 CD25  T cells was monitored in cyclophosphamide-
treated naive neu-N mice. A significant decrease (P  
0.0001) in the total number of CD4 CD25  T cells was ob-
served in the LN 2 d after cyclophosphamide treatment (Fig.
6 A). This decrease was detected in the LNs at the time when
T cell induction would be occurring in vaccinated mice. The
percentage of CD4  T cells that are CD25  was also moni-
tored for 2 wk in cyclophosphamide-treated neu-N mice. A
significant drop (P   0.0007) in the percent of CD4 CD25 
was also seen within 2 d after cyclophosphamide treatment,
which then recovered over the next 2 wk (Fig. 6 B).
Because cyclophosphamide has a relatively modest effect
on total CD4 CD25  T cell numbers, and the population of
CD4 CD25  T cells in whole LNs is polyclonal, it is possi-
ble that cyclophosphamide affects a specific subset of CD4 
CD25  T cells. Others have shown that CD4 CD25  T
cells proliferate in the steady state in response to self-antigen
(28). Thus, cyclophosphamide may act on the CD4 CD25 
T reg cell population that is proliferating to self-antigen in
our model. To test this possibility, neu-N mice were given
cyclophosphamide or PBS on day 0 and then pulsed with a
2-mg dose of bromodeoxyuridine (BrdU) on day 1. On day
2, LNs were harvested, and lymphocytes were stained for
CD4, CD8, CD25, and BrdU. In the groups injected with
PBS and BrdU,  1% of CD8  T cells and  0.3% of
CD4 CD25  T cells incorporated BrdU. In contrast, 6.8%
of CD4 CD25  T cells incorporated BrdU. When treated
with cyclophosphamide, the percent of CD4 CD25  T
cells that incorporated BrdU was not above background
(Fig. 6 C). Thus, cyclophosphamide seems to eliminate ac-
Table I. koff for RNEU420-429-specific T cell linesa
T cell line koff  SD
(min 1)
FVB/N 41.5   10 3  10.1   10 3
neu-N 272.7   10 3  164.1   10 3
neu-N   chemotherapy 17.5   10 3  3.9   10 3
aAssay performed as described in Materials and methods. Values represent an aver-
age of three experiments per T cell line.
Figure 5. High-avidity, RNEU420-429-specific T cells can be identi-
fied in polyclonal T cell populations from neu-N mice given vaccine 
and cyclophosphamide chemotherapy that rejected neu-expressing 
tumors. CD8  enriched splenocytes were stained with decreasing 
amounts of H-2Dq-RNEU420-429 tetramer. Three representative samples are 
shown. Plots on the left are gated on CD8 , CD62Llo lymphocytes and 
show the 1:50 dilution of tetramer. Corresponding plots on the right show 
histograms gating on the CD8 , tetramer  cells stained with decreasing 
amounts of tetramer.JEM VOL. 201, May 16, 2005 1597
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tively cycling CD4 CD25  T cells. These data provide
strong evidence that cyclophosphamide administration de-
pletes cycling T reg cells, allowing the generation and activa-
tion of high-avidity RNEU420-429-specific T cells.
Direct depletion of CD4 CD25  T cells with anti-CD25 
antibody allows the detection of high-avidity 
RNEU420-429-specific T cells
Based on these studies, cyclophosphamide seems to act on T
reg cells that suppress high-avidity RNEU420-429-specific T
cell activity in neu-N mice. However, it is also possible that
cyclophosphamide enhances high-avidity RNEU420-429-spe-
cific CD8  T cells through a T reg cell–independent mech-
anism. To address this issue, T reg cells were targeted di-
rectly with the anti-CD25–depleting antibody, PC61, given
4 d before vaccination (29). We first confirmed that a single
1.0-mg dose of PC61 decreased the total number of
CD4 CD25  T cells from 12% of total CD4  T cells to less
than 3% in neu-N mice (Fig. 7 A). Importantly, direct deple-
tion of CD4 CD25  T cells with PC61 resulted in the abil-
ity to isolate RNEU420-429-specific T cells from 10–20% of
mice (Fig. 7 B). This finding correlated with enhanced vaccine-
induced prevention of tumor progression that was similar to
observations with cyclophosphamide-modulated vaccine ther-
apy (unpublished data). Furthermore, RNEU420-429-specific
T cells isolated from mice depleted of CD4 CD25  T cells
with PC61 before vaccination were high avidity, because
they could be detected with multiple dilutions of the H-2Dq-
RNEU420-429 tetramer (Fig. 7 C).
CD4 CD25  T cells from neu-N mice suppress vaccine-
induced RNEU420-429-specific CD8  T cells in vaccinated, 
nontolerized FVB/N mice
Additional studies were performed to confirm further that
CD4 CD25  T reg cells directly suppress RNEU420-429-spe-
cific CD8  T cell responses. Specifically, groups of parental
nontolerized FVB/N mice were vaccinated either alone or
1 d after receiving 5   105 adoptively transferred CD4 
CD25  T cells. Because the vaccine is extremely immuno-
genic in the nontolerant FVB/N mice, the CD4 CD25  T
cells were isolated from tumor-bearing, vaccinated neu-N
mice with the goal of transferring an activated T reg cell
population. After 2 wk, mice receiving vaccine alone dem-
onstrated RNEU420-429-specific CD8  T cells ranging from
1–3%. However, mice receiving adoptively transferred CD4 
CD25  T cells demonstrated a significant (P   0.016) de-
crease in RNEU420-429-specific CD8  T cell responses rang-
ing from 0.25–1% (Fig. 8). These data provide additional
evidence that CD4 CD25  T reg cells have a direct sup-
pressing effect on RNEU420-429-specific CD8  T cell re-
sponses. Despite the decrease in the percent of RNEU420-429-
specific T cells, the T cells that were activated seemed to be
functional, because no suppression of the antitumor response
was observed when the FVB/N mice that received the T reg
cell transfer were given a neu-expressing tumor challenge
(unpublished data).
DISCUSSION
We previously identified RNEU420-429 as the immunodomi-
nant epitope encoded by the rat neu gene and recognized by
the majority of T cell lines and clones derived from vacci-
nated FVB/N mice. We now report three new findings that
give insight into the mechanisms of CD8  T cell tolerance
in neu-N transgenic mice. First, treatment of neu-N mice
with immunomodulating doses of chemotherapy in se-
quence with neu-targeted vaccination uncovers high-avidity
RNEU420-429-specific CD8  T cell activity that is associated
with more effective eradication of neu-expressing tumors in
vivo. Second, one mechanism by which cyclophosphamide
Figure 6. Cyclophosphamide depletes cycling CD4 CD25  T cells. 
(A) Axillary LNs from PBS- or cyclophosphamide-treated neu-N mice (10/
group) were isolated 48 h after cyclophosphamide administration. Total cell 
number in each LN was determined, and the number of CD4 CD25  T cells 
was calculated based on the percent of CD4 CD25  T cells determined by 
flow cytometry. (B) LN cells from neu-N mice (4/group) given cyclophos-
phamide were isolated and analyzed for the number of CD4 CD25  T cells 
on the indicated days. The experiment was repeated three times. (C) Neu-N 
mice were given cyclophosphamide or PBS on day 0. On day 1, the mice 
were given a 2-mg dose of BrdU. On day 2, LNs were harvested, and the 
lymphocytes were stained for CD4, CD8, CD25, and BrdU. This experiment 
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chemotherapy enhances vaccine-induced RNEU420-429-spe-
cific T cells is through deletion of cycling CD4 CD25  T
reg cells. Third, unlike FVB/N mice, neu-targeted vaccine
given alone to neu-N mice induces lower-avidity RNEU420-429-
specific T cell responses.
To our knowledge, this is the first report demonstrating
the unmasking of high-avidity CD8  T cell responses against
a naturally expressed tissue-specific tumor antigen in a mu-
rine model of tolerance. Others have reported the induction
of low-avidity antigen-specific T cells upon vaccination of
transgenic mice for other model tumor antigens as compared
with nontransgenic mice (8, 30, 31). In some cases, T cell
avidity can be improved by repeated in vitro stimulation of T
cells (11) or repeated antigen exposure in vivo (32). How-
ever, the initial generation of high-avidity T cells after in vivo
vaccination regimens has not been previously demonstrated.
In several models of tumor tolerance, low-avidity T cells
induced to recognize self-antigens were sufficient to suppress
growth of tumors expressing the antigen (8). However, most
other studies have shown that high-avidity T cells are supe-
rior antigen-recognition and lytic agents than their low-
avidity counterparts (33–36). In one study, low-avidity CTL
generated against the melanoma antigen gp100 were capable
of lysing only peptide-pulsed cells, whereas high-avidity
CTL efficiently lysed endogenously expressed levels of pep-
tide presented by gp100-expressing tumor cells (37). Simi-
larly, high-avidity CTL isolated from B16–GM-CSF–vacci-
nated mice showed superior in vitro and in vivo antitumor
Figure 7. High-avidity RNEU420-429-specific CD8  T cells are 
detected after depletion of CD4 CD25  T reg cells with the CD25  
T cell-depleting antibody, PC61. (A) Depletion was obtained using a 
single 1-mg dose of PC61 given 4 d before analysis. Splenocytes were 
isolated and stained with the noncompeting anti-CD25 antibody 7D4. 
(B) Mice were given 1 mg of PC61 4 d before vaccination. 2 wk after vacci-
nation, splenocytes were isolated, and ICS was performed. Shown are the 
percent of CD8  T cells that were RNEU420-429-specific. Similar results have 
been seen in more than six independent experiments. (C) Splenocytes from 
(B) were stimulated for 1 wk with RNEU420-429 and then stained with de-
creasing amounts of H-2Dq/RNEU420-429 tetramer. Three representative 
samples are shown. Plots on the left are gated on CD8 , CD62Llo lympho-
cytes and show the 1:50 dilution of tetramer. Corresponding plots on the 
right show histograms gating on the CD8 , tetramer  cells stained with 
decreasing amounts of tetramer.
Figure 8. Adoptive transfer of CD4 CD25  T cells from vaccinated, 
tumor-bearing neu-N mice suppresses the activation of RNEU420-429-
specific CD8  T cells in FVB/N mice. CD4 CD25  T cells from vaccinated, 
tumor-bearing neu-N mice were isolated by cell sorting. 5   105 CD4 CD25  
T reg cells were transferred into naive FVB/N mice that were vaccinated 
the following day. On day 14 after vaccination, splenic CD8  T cells were 
isolated, and ICS was performed. Shown are the percent of total CD8  T 
cells that produced IFN-  in response to RNEU420-429. This study was re-
peated twice with similar results.  , individual mice; solid line, average.JEM VOL. 201, May 16, 2005 1599
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activity when compared with lower-avidity CTL (38). In
our mammary tumor model, the development of high-avid-
ity T cells is associated with protection against tumor out-
growth and an apparent abatement of the tolerance exhibited
in neu-N mice. We have shown that high-avidity neu-spe-
cific T cells can be recovered in 10–30% of neu-N mice
treated with immune-modulating doses of chemotherapy. In
addition to the T cell line shown in this paper, we have iso-
lated other high-avidity RNEU420-429-specific T cell lines
from  neu-N mice that have eradicated established trans-
planted mammary tumors after vaccination and cyclophos-
phamide chemotherapy. It is not possible, however, to isolate
high-avidity RNEU420-429-specific T cells from tumor-bear-
ing neu-N mice given vaccine alone. These data provide ad-
ditional evidence that optimal antitumor immunization will
depend in part on the ability to induce high-avidity T cells
specific for immunodominant epitopes contained in tumor
antigens.
Our data also illustrate the importance of using the opti-
mal vaccine strategy when targeting tumor antigens. We
show that unless vaccine is combined with deletion or inhi-
bition of T reg cells, the most potent CD8  T cells will not
be recruited to the antitumor immune response. Similar
findings have been reported recently by Antony et al. (39)
showing in an adoptive transfer model that optimal vaccine
against melanoma antigens could be achieved only when T
reg cells were removed. Other recent reports suggest that the
vaccine itself can overcome the influence of T reg cells if sig-
naling through Toll-like receptors is involved (e.g., a vac-
cinia-based vaccine) (40). However, our experience in the
neu-N mice suggests otherwise. Our early reports studying
the neu-specific immune responses in the neu-N mice
showed no difference between our GM-CSF–secreting vac-
cine and a neu-expressing vaccinia vaccine (16). Further-
more, the high potency of our GM-CSF vaccine approach is
supported by our earlier report that this vaccine given as a
single agent results in the regression of 40-mm2 tumors in
the FVB/N nontolerized mice (17).
The studies presented here focused on the mechanism of
cyclophosphamide in potentiating the immune response in
vaccinated neu-N mice. We are currently investigating the
mechanism of doxorubicin (Dox) in the combined chemo-
therapy regimen. However, our previous data do not sup-
port a role for Dox in eliminating T reg cell activity, because
Dox inhibits vaccine-induced immune responses when
given at the time of T cell priming (17). Dox enhances the
effect of vaccine only when given at the time of T cell ex-
pansion, probably by enhancing the T cell’s cytolytic activity
(41). Thus, the ability to uncover high-avidity RNEU420-429-
specific CD8  T cells in the neu-N mice is not dependent
on Dox, because similar results were seen in mice given cy-
clophosphamide and Dox, cyclophosphamide alone, or PC61
in combination with vaccine.
In this study avidity is defined in part as the degree to
which a T cell binds MHC/peptide tetramer. Although nu-
merous studies have shown a correlation between tetramer
binding and T cell function (36, 42, 43), others have not (34,
43, 44). Here, the T cell lines that showed high-intensity
tetramer staining were able to lyse neu-expressing tumor
cells to a greater degree than the T cell line that displayed
poor tetramer binding. Many investigations have also mea-
sured avidity of T cells by their ability to lyse peptide-pulsed
cells (7, 8, 30, 37, 45). We confirmed these differences in T
cell avidity for the H-2Dq/RNEU420-429 MHC/peptide
complex by determining TCR koff rates for each T cell line.
The T cell line that showed the lowest amount of surface
tetramer binding had the fastest koff rate of the three lines an-
alyzed. To the best of our knowledge, this is the first time
the TCR koff rate has been quantitated for tolerized versus
nontolerized T cells in a murine tumor model.
It is still unexplained why adding cyclophosphamide
chemotherapy to the vaccine regimen consistently over-
comes tolerance in, at most, 30% of treated mice. Also, each
mouse seems to respond in an all-or-none fashion. It is pos-
sible that improving the success of cyclophosphamide modu-
lation depends on the long-term depletion or inhibition of T
reg cell function. We have found that the T reg cell popula-
tion in neu-N mice recovers within 2 wk of cyclophospha-
mide treatment. The kinetics is similar to T reg cell recovery
after depletion with the CD25-targeted antibody, PC61
(29). It is more difficult to study recurrent treatment with
cyclophosphamide, because lymphopenia can abrogate the
vaccine-induced antigen-specific T cell response. CD25-tar-
geted depleting antibodies are also difficult to give after an
initial dose, because they also target vaccine-induced, acti-
vated T cells that up-regulate CD25. Furthermore, other
systemic and local mechanisms within the tumor’s microen-
vironment are probably active and require modulation to
allow the long-term tumor trafficking and survival of high-
avidity antigen-specific T cells. Studies are underway to elu-
cidate additional mechanisms of peripheral tolerance in the
neu-N mice.
Based on the data described in this report, we propose the
following as a model to explain one mechanism of CD8  T
cell tolerance in neu-N mice. CTL from vaccinated neu-N
mice that are specific for the immunodominant epitope are
rare and are of lower avidity than T cells derived from paren-
tal FVB/N mice. These low-avidity T cells are also either
weak lytic agents or anergized T cells. However, higher-avid-
ity T cells (similar in avidity to those derived from nontolerant
FVB/N mice) specific for the immunodominant epitope can
escape thymic deletion and are actively suppressed in the pe-
riphery of these mice. Our data strongly support CD4 
CD25  T reg cell involvement as one mechanism for the in-
duction of peripheral tolerance. Central tolerance is unlikely
to be a major mechanism, because high-avidity CD8  T cells
specific for RNEU420-429 can be recovered from vaccinated
neu-N mice treated with T reg cell-depleting agents such as
cyclophosphamide or PC61. It is possible that central toler-
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periphery by immature dendritic cells when mature mice be-
gin to overexpress neu in the periphery. Without the proper
maturation signals, the outcome is likely to be cross-tolerance
of CTL rather than cross-priming (46). However, our data
demonstrate that neu-N mice develop CD4 CD25  T reg
cells that actively suppress RNEU420-429-specific T cells (47).
This is probably one mechanism of peripheral tolerance at
work in our model, because treatment with cyclophospha-
mide or PC61, which have been reported to delete or inhibit
T reg cells, reverses tolerance when combined with vaccine
(18–21). This possibility is further supported by our data
showing that cyclophosphamide selectively inhibits cycling
CD4 CD25  T reg cells in neu-N mice.
In summary, we have described one mechanism of
CD8  T cell tolerance to the protooncogene neu expressed
in neu-N transgenic mice. Further investigation is needed to
determine the additional mechanisms involved in the induc-
tion of neu-directed immune tolerance. However, our data
strongly suggest that the most effective antitumor vaccine
regimens must include a T reg cell-targeting agent to allow
the most potent tumor-reactive T cells to be activated.
MATERIALS AND METHODS
Mice. All mice used were between 8 and 12 wk of age. FVB/N mice were
purchased from the National Cancer Institute and Taconic Laboratories.
neu-N mice (15), provided by William Muller, were bred to homozygosity
as verified by Southern blot analysis (16) and bred and housed at Johns
Hopkins University. All experiments were performed in accordance with
protocols approved by the Animal Care and Use Committee of the Johns
Hopkins University School of Medicine.
Cell lines and media. The GM-CSF–secreting vaccine cell lines 3T3GM
and 3T3neuGM (expressing neu) were generated and grown as previously
described (24). The IT22, IT22neu, and T2Dq cell lines used for targets in
T cell assays were also previously described (24). The NT2 and NT5 neu-
expressing tumor lines were derived from spontaneously arising mammary
tumors excised from neu-N mice. NT2 cells used in tumor-challenge ex-
periments express stable neu and MHC class I. NT5 was retrovirally in-
fected with the human B7-1 gene to generate NT5B7-1 cells as previously
described (16, 17).
T cell lines were generated from FVB/N or neu-N mice given vaccine
(3T3neuGM) or from neu-N mice that rejected an NT2 tumor challenge
after being given vaccine and cyclophosphamide chemotherapy (see Immu-
nization protocols). Splenocytes were initially stimulated every 5 d with ir-
radiated, IFN-  treated NT5B7-1 cells and then every 9 d by addition of ir-
radiated 3T3neuB7-1 cells and FVB/N-derived splenocytes. T cells were
maintained at 37 C and 5% CO2 in CTL media (RPMI 1640 supplemented
with 10% FBS, 1% L-glutamine, 0.1 mM 2-mercaptoethanol (Sigma-Aldrich),
and 0.5% penicillin/streptomycin supplemented with 10 cetus U/ml mu-
rine IL-2, a supernatant from B16 IL-2 line (17).
Peptides. RNEU420-429 (PDSLRDLSVF) and NP118-126 (RPQASGVYM)
peptides were synthesized at  95% purity and purchased from either the
Johns Hopkins Biosynthesis and Sequence Facility or from Macromolecular
Resources of Colorado State University. The NP118-126 peptide is from the
lymphocytic choriomeningitis virus nucleoprotein (25) and is used as an ir-
relevant H2-Dq–binding peptide.
Antibodies and tetramer and flow cytometric analysis. mAb hybrid-
oma supernatants (all acquired from the American Type Culture Collection)
were used for staining T cell lines: B20.6 (TCR V 2), KT4 (TCR V 4),
and RR4-7 (TCR V 6). Directly conjugated antibodies anti-CD3 FITC,
anti-CD4 CyChrome, anti-CD8  CyChrome, anti-CD8  FITC, anti-
CD25 PE (PC61 and 7D4), anti-CD62L allophycocyanin, and anti-IFN- 
PE were purchased from BD Biosciences. The CD25-depleting antibody
PC61 was purified from the supernatant of PC61.5.3 hybridoma (American
Type Culture Collection) grown in Protein Free Hybridoma Media II
(Invitrogen).
The H-2Dq/RNEU420-429 tetramer was constructed using previously
described methods (48). Tetramer staining was performed by first staining
only for CD8 (T cell lines) or CD8 and CD62L (ex vivo experiments).
Cells were washed, and tetramer was added at varying dilutions and incu-
bated for 30 min at 8–12 C. Cells were washed twice and immediately
fixed with fresh 1% paraformaldehyde in PBS. Tetramer staining was ana-
lyzed by gating only on CD8  cells (T cell lines) or CD8 , CD62Llo cells
(ex vivo experiments).
ICS was performed using the mouse ICS kit from BD Biosciences for
murine IFN- . Purified T cells were incubated for 6–12 h with an equal ra-
tio of indicated targets (IT22neu, IT22, or T2Dq cells pulsed with either
RNEU420-429 or NP118-126) in the presence of GolgiStop (BD Biosciences).
Cells were then stained for CD8, fixed and permeabilized, and stained with
anti-IFN-  PE. Analysis was performed by gating on CD8  cells and calcu-
lating the percent of total CD8  cells that were also IFN-  . The percent
of antigen-specific cells was calculated by subtracting the percent of IFN-  
cells in the irrelevant antigen sample from the percent of IFN-   cells in
the relevant antigen sample.
Flow cytometric data were collected using BD FACScan and BD
FACSCalibur cytometers (BD Biosciences). Data were analyzed using
CELLQuest (BD Biosciences) and FlowJo software (Tree Star, Inc.).
Immunization protocols. Mice were given vaccine (3T3neuGM), or
mock vaccine (3T3GM cells) alone or in combination with cyclophospha-
mide, or cyclophosphamide plus Dox as described previously (17), or PC61
depletion. Mice given vaccine alone were injected s.c. with 3   106 total
cells divided equally among one forelimb and two hind limbs. Mice given
vaccine and cyclophosphamide received a single i.p. injection of cyclophos-
phamide, 100 mg/kg in 0.5 ml (Mead Johnson), on day  1 and vaccine (as
described previously) on day 0. Vaccine given with cyclophosphamide and
Dox included cyclophosphamide on day  1, vaccine on day 0, and Dox, 5
mg/kg given i.v. in 0.5 ml (Gensia Sicor Pharmaceuticals Inc.) on day 7
(this regimen is referred to as cyclophosphamide chemotherapy in the text).
We and others previously found that Dox given at the time of T cell expan-
sion can enhance the cytotoxic function of CD8  T cells (17, 41). PC61-
depletion studies were performed by giving one dose of PC61 (1 mg i.p.)
on day  4 followed by vaccine on day 0. In tumor-challenge experiments,
NT2 tumor cells (5   104 cells injected s.c. in the mammary fat pad) were
injected either on day  3 or on day 14. Mice were monitored for tumor
outgrowth twice per week.
Adoptive transfer experiments. neu-N donor mice were either naive or
given an NT2 tumor challenge on day  3 and 3T3neuGM vaccine on day
0. 2 wk after vaccination, donor CD4  and CD8  splenic T cells were iso-
lated using MACS negative isolation kits (Miltenyi Biotec). Donor
CD4 CD25  and CD4 CD25  splenic subsets were isolated from purified
CD4  T cells by staining for CD25 and sorting the positive and negative
fractions using a FACSVantage cell sorter (Becton Dickinson). All T cell
subsets were analyzed by flow cytometry to confirm purity. T cells were
washed with PBS and injected i.v. into recipient mice.
Bromodeoxyuridine incorporation assay. neu-N mice were given cy-
clophosphamide or PBS i.p. on day 0. On day 1, mice were given a 2-mg
dose of BrdU injected i.p. On day 2, axillary LN cells were isolated,
washed, and stained using the FITC BrdU Flow Kit (BD Biosciences).
Chromium-release assays. Lysis assays were performed in triplicate in
96-well V-bottom plates as previously described (16). After 4-h incubation,JEM VOL. 201, May 16, 2005 1601
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supernatant was assayed for 51Cr release and the percentage of specific lysis
was determined by the formula: (51Cr release sample   spontaneous 51Cr
release)/(maximum 51Cr release   spontaneous 51Cr release)   100.
Tetramer off-rate experiments. T cells were washed and resuspended
at 106 in 100- l buffer. Cells were incubated with 8   10 3 M H-2Dq/
RNEU420-429 tetramer for 1 h at 4 C and then 20-fold molar excess of the
H-2Dq antibody 30–5-7S (American Type Culture Collection) was added
to prevent tetramer from rebinding T cells. Mean fluorescence intensity of
tetramer staining was determined by flow cytometry at various time points
from 0 to 240 min. Resulting data were fit to a first-order exponential de-
cay using the Origin program (Microcal Software, Inc.). Off-rates were cal-
culated as the reciprocal of t1.
Statistical analysis. Statistical significance of the tumor-free survival plots
was determined using the log rank test. A Student’s t test was applied to
compare statistical significance between treatment groups. All analysis was
performed using Prism 4 software (GraphPad Software).
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